share_log

Regeneron Pharmaceuticals | 8-K: Current report

リジェネロン ファーマシューティカルズ | 8-K:臨時報告書

SEC ·  2024/06/21 04:03

Moomoo AIのまとめ

At Regeneron's 2024 Annual Meeting held on June 14, shareholders approved all proposed items on the agenda. Four Class III directors were elected to serve until 2027, including N. Anthony Coles, Kathryn Guarini, Arthur F. Ryan, and George L. Sing. Additionally, David P. Schenkein was elected as Class II director to serve until 2026.Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024, with 111.35 million votes in favor. The advisory vote on executive compensation received strong support with 106.67 million votes in favor.Notably, the non-binding shareholder proposal requesting simple majority voting requirements was approved with 85.9 million votes in favor, representing significant shareholder support for this governance change.
At Regeneron's 2024 Annual Meeting held on June 14, shareholders approved all proposed items on the agenda. Four Class III directors were elected to serve until 2027, including N. Anthony Coles, Kathryn Guarini, Arthur F. Ryan, and George L. Sing. Additionally, David P. Schenkein was elected as Class II director to serve until 2026.Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024, with 111.35 million votes in favor. The advisory vote on executive compensation received strong support with 106.67 million votes in favor.Notably, the non-binding shareholder proposal requesting simple majority voting requirements was approved with 85.9 million votes in favor, representing significant shareholder support for this governance change.
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報